An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05315713 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated due to Sponsor decision.

Conditions

Non-Hodgkin Lymphoma, Follicular Lymphoma

Interventions

DRUG: Mosunetuzumab SC
DRUG: Tiragolumab
DRUG: Atezolizumab
OTHER: Tocilizumab

Sponsor

Hoffmann-La Roche